Has the Israeli Biotech Industry valuation changed over the past few years?

Investors are relatively neutral on the Israeli Biotechs industry at the moment, indicating that they anticipate long term growth rates to remain steady. The industry is trading close to its 3-year average PS ratio of 3.5x.

Which industries have driven the changes within the Israeli Healthcare industry?

There are no additional sub-industries under this industry.

Israeli (TA) Biotech Industry Analysis

Date	Market Cap	Revenue	Earnings	PE	Absolute PE	PS
Mon, 17 Aug 2026	₪1.8b	₪578.0m	-₪108,734,467.80	11.8x	-16.6x	3.1x
Wed, 15 Jul 2026	₪1.9b	₪557.1m	-₪115,129,321.60	12.5x	-16.4x	3.4x
Fri, 12 Jun 2026	₪2.1b	₪543.4m	-₪89,604,783.50	7.3x	-23.1x	3.8x
Sun, 10 May 2026	₪2.4b	₪539.6m	-₪57,388,250.60	7.4x	-41.7x	4.4x
Tue, 07 Apr 2026	₪2.4b	₪595.3m	-₪54,187,718.00	6.5x	-44.9x	4.1x
Thu, 05 Mar 2026	₪2.6b	₪603.5m	-₪60,083,991.40	15.7x	-43.7x	4.4x
Sat, 31 Jan 2026	₪2.4b	₪607.3m	-₪60,123,746.00	14.5x	-40.4x	4x
Mon, 29 Dec 2025	₪2.2b	₪630.9m	-₪66,490,643.50	12.4x	-32.5x	3.4x
Wed, 26 Nov 2025	₪2.1b	₪647.7m	-₪66,751,295.50	12.1x	-31.1x	3.2x
Fri, 24 Oct 2025	₪2.1b	₪651.5m	-₪94,343,554.00	12.9x	-22x	3.2x
Sun, 21 Sep 2025	₪2.1b	₪660.3m	-₪99,721,214.00	12.9x	-21.4x	3.2x
Tue, 19 Aug 2025	₪2.2b	₪662.0m	-₪136,383,406.00	13.6x	-16.2x	3.3x
Thu, 17 Jul 2025	₪2.3b	₪665.9m	-₪128,555,259.40	16x	-17.5x	3.4x
Sat, 14 Jun 2025	₪2.1b	₪719.6m	-₪131,668,184.80	14.5x	-16.3x	3x
Mon, 12 May 2025	₪2.2b	₪713.0m	-₪161,744,185.90	16.6x	-13.7x	3.1x
Wed, 09 Apr 2025	₪2.0b	₪768.5m	-₪164,813,905.60	14.2x	-12.2x	2.6x
Fri, 07 Mar 2025	₪2.3b	₪698.6m	-₪207,825,780.80	17.6x	-10.9x	3.2x
Sun, 02 Feb 2025	₪2.1b	₪679.8m	-₪227,567,315.00	15.1x	-9.4x	3.2x
Tue, 31 Dec 2024	₪1.9b	₪695.2m	-₪228,064,333.20	13.5x	-8.5x	2.8x
Thu, 28 Nov 2024	₪1.9b	₪695.0m	-₪227,742,771.60	13.3x	-8.6x	2.8x
Sat, 26 Oct 2024	₪2.0b	₪694.3m	-₪259,728,498.20	13.1x	-7.8x	2.9x
Mon, 23 Sep 2024	₪2.1b	₪692.0m	-₪259,199,477.00	13x	-8x	3x
Wed, 21 Aug 2024	₪2.2b	₪674.3m	-₪226,523,426.00	14.7x	-9.7x	3.2x
Fri, 19 Jul 2024	₪2.2b	₪629.7m	-₪325,424,190.50	17.2x	-6.8x	3.5x
Sun, 16 Jun 2024	₪2.0b	₪641.4m	-₪329,957,041.00	15.7x	-6.2x	3.2x
Tue, 14 May 2024	₪2.1b	₪603.0m	-₪389,297,179.10	16.6x	-5.5x	3.6x
Thu, 11 Apr 2024	₪2.1b	₪621.2m	-₪410,832,803.90	21.6x	-5.2x	3.4x
Sat, 09 Mar 2024	₪2.4b	₪537.7m	-₪365,135,415.70	53.2x	-6.6x	4.5x
Mon, 05 Feb 2024	₪2.3b	₪626.5m	-₪398,065,458.00	61x	-5.7x	3.6x
Wed, 03 Jan 2024	₪2.4b	₪625.3m	-₪397,481,852.00	63.3x	-6.1x	3.9x
Fri, 01 Dec 2023	₪2.1b	₪637.9m	-₪417,150,433.00	56x	-4.9x	3.2x
Sun, 29 Oct 2023	₪1.9b	₪655.0m	-₪430,593,975.00	70.8x	-4.5x	3x
Tue, 26 Sep 2023	₪2.3b	₪619.1m	-₪379,560,038.00	73.6x	-6.1x	3.7x
Thu, 24 Aug 2023	₪1.9b	₪609.8m	-₪336,786,986.00	65.1x	-5.6x	3.1x


IL Market	-1.11%
Healthcare	-2.34%
Biotech	-1.36%
Biotech	-1.36%

Company	Last Price	7D	1Y	Valuation
KMDA Kamada	₪22.87	6.7% +₪82.5m	-7.4%	PE20.1x
MTLF Matricelf	₪2.66	4.2% +₪3.2m	4.0%	PB7.7x
CANF Can-Fite BioPharma	₪5.16	1.5% +₪334.2k	-82.8%	PS18.5x

Announcement • Aug 13

Can-Fite Biopharma Provides Update on Regulatory Status of Phase Iii Drug Candidates Piclidenoson and Namodenoson

Can-Fite BioPharma provided an update on the regulatory status of its two lead drug candidates, Piclidenoson and Namodenoson. Both drug candidates are being advanced in Phase III clinical development programs under regulatory frameworks established with the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), providing defined regulatory pathways toward potential marketing approval. Namodenoson, Can-Fite’s orally administered A3 adenosine receptor (A3AR) agonist, is currently being evaluated in a pivotal Phase III study for the treatment of patients with advanced liver cancer, hepatocellular carcinoma (HCC) and underlying Child-Pugh B7 liver cirrhosis. The Phase III study is being conducted under regulatory guidance from both the FDA and EMA and is designed to support potential marketing authorization applications in the United States and Europe, if the study meets its predefined efficacy and safety endpoints. Piclidenoson, Can-Fite’s oral A3AR agonist for inflammatory diseases, is currently being evaluated in a Phase III clinical program for the treatment of moderate-to-severe plaque psoriasis. Can-Fite’s clinical development strategy is focused on advancing its lead drug candidates through late-stage clinical development under regulatory pathways established with leading regulatory authorities. Namodenoson’s FDA Fast Track and FDA and EMA Orphan Drug designations provide additional regulatory advantages as the Company advances its pivotal HCC program, while Piclidenoson is progressing through Phase III development in psoriasis. Can-Fite believes that the advanced regulatory status of both programs significantly strengthens the Company’s late-stage clinical pipeline and provides a clear framework for advancing Piclidenoson and Namodenoson toward potential regulatory submissions and commercialization. Piclidenoson recently reported topline results in a Phase 3 trial for psoriasis and commenced a pivotal Phase 3 trial. Can-Fite’s liver drug, Namodenoson, is being evaluated in a Phase III trial for hepatocellular carcinoma (HCC), a Phase 2b trial for the treatment of MASH, and in a Phase 2a study in pancreatic cancer. Namodenoson has been granted Orphan Drug Designation in the U.S. and Europe and Fast Track Designation as a second line treatment for HCC by the U.S. Food and Drug Administration. Namodenoson has also shown proof of concept to potentially treat other cancers including colon, prostate, and melanoma. CF602, the Company’s third drug candidate, has shown efficacy in the treatment of erectile dysfunction. These drugs have an excellent safety profile with experience in over 1,600 patients in clinical studies to date.

Announcement • Jul 08

Biolinerx and Hemispherian Announce New Preclinical Data Demonstrating Strong Synergistic Effect Between Glix1 and Parp Inhibitor in A Patient-Derived Ovarian Cancer Xenograft Model

BioLineRx Ltd. and Hemispherian AS announced highly encouraging new preclinical data demonstrating strong synergy between GLIX1 and PARP inhibitors in a patient-derived xenograft (PDX) model of ovarian cancer. Synergy was demonstrated in a combination arm of GLIX1 and the PARP inhibitor olaparib at low doses, with substantially better efficacy compared to the control arm and compared to each drug individually at its optimal dose. GLIX1 in combination with olaparib also showed comparable efficacy to that seen with the chemotherapy drug cisplatin. Results reinforce synthetic lethality between GLIX1 and PARP inhibitors, indicating that GLIX1 can broaden the use of PARPi in ovarian cancer. Ovarian cancer remains a major therapeutic challenge, particularly in homologous recombination (HR)-proficient disease where PARP inhibitors (PARPi) presently have limited efficacy, as well as for patients with platinum-resistance. GLIX1 in combination with PARPi is expected to result in synthetic lethality, a mechanism in which GLIX1-induced single-stranded DNA breaks overcome PARP inhibitors' requirement for HR-deficiency, enabling synergistic activity in HR-proficient cancers. This effect was first observed in vitro, where GLIX1 showed reproducible synergy across different PARP inhibitors and multiple HR-proficient ovarian cancer cell lines, with very high ZIP synergy scores. Today's results represent a compelling in vivo confirmation of GLIX1 and PARPi synergy from an HR-proficient ovarian cancer PDX model. The study included six arms: cisplatin, GLIX1 monotherapy and olaparib monotherapy (all at doses expected to be optimal), low-dose GLIX1, a low-dose GLIX1/olaparib combination arm, and a control arm. Results show substantially better efficacy in the combination arm versus the control arm and versus the monotherapy arms, despite using lower doses in the combination arm. The low-dose GLIX1/olaparib combination tumor reduction was similar to cisplatin, the current chemotherapy benchmark. BioLineRx and Hemispherian plan to present the data from this study at one or more future medical conferences. GLIX1 is a first-in-class, orally administered, brain penetrating, small molecule activator of the Ten-Eleven Translocation 2 (TET2) pathway that is commonly inhibited in cancer. Activating the novel TET2 pathway by GLIX1 overwhelms the DNA repair capacity of cancer cells, resulting in apoptotic cancer cell death. The Phase 1/2a trial is an open-label, multicenter trial. Part 1 of the trial is a dose escalation study where patients receive GLIX1 daily as monotherapy. This part is expected to recruit up to 30 patients with recurrent and progressive GBM and other high-grade gliomas. The primary objective is to establish a maximum tolerated dose (MTD) and/or a recommended dose based on safety, PK/PD and preliminary efficacy. Updates to the Phase 1/2a trial are anticipated during Second Half 2026, with full results on the dose escalation part expected in 2027. The Phase 2a expansion part of the trial is planned to include additional indications, including newly diagnosed GBM, as well as select cancers, with GLIX1 as monotherapy or in combination with standard of care (including in combination with PARP inhibitors). These cohorts are expected to identify preliminary efficacy, PD assessments and dose optimization data, serving as the basis for a rapid and effective advanced clinical development plan.

Israeli (TA) Biotech Industry Analysis

Industry Valuation and Performance

Industry Trends

Top Stock Gainers and Losers

Latest News

Chaime Orle Plans to Resign as Chief Financial Officer of Kamada Ltd, Effective December 31, 2026

Can-Fite Biopharma Provides Update on Regulatory Status of Phase Iii Drug Candidates Piclidenoson and Namodenoson

Insufficient new directors

Evogene Ltd., Annual General Meeting, Sep 04, 2026

Less than half of directors are independent

New minor risk - Market cap size

Matricelf Ltd. Receives Approval to Begin Patient Identification and Blood Collection for Planned First-In-Human Spinal Cord Injury Study

Biolinerx and Hemispherian Announce New Preclinical Data Demonstrating Strong Synergistic Effect Between Glix1 and Parp Inhibitor in A Patient-Derived Ovarian Cancer Xenograft Model

New major risk - Share price stability

New minor risk - Financial data availability